Clinical trials: Irinotecan
Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8
- Trial name
- NCT05296681
- Testing
- NBT-NM108
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Howard S. Hochster, MD
Advanced Esophageal Carcinoma
mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial
There are few studies about 2nd line treatment in advanced esophageal carcinoma(AEC), some showed that irinotecan may be effective.
- Trial name
- NCT01044420
- Testing
- mFOLFIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University
Metastatic Colorectal Cancer
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are…
- Trial name
- NCT04929223
- Testing
- Inavolisib, Bevacizumab, Cetuximab
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer
the aim of this study is to observe the effect of irinotecan-based regimen in patients with advanced colorectal cancer.
- Trial name
- NCT01566942
- Testing
- Oxaliplatin, Irinotecan
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Malignant Glioma of Brain
Panitumumab and Irinotecan for Malignant Gliomas
This is a phase II study of the combination of panitumumab with irinotecan in malignant glioma patients. The primary objective of the study is to determine the activity of the combination of panitumumab with irinotecan as…
- Trial name
- NCT01017653
- Testing
- Irinotecan, Panitumumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Annick Desjardins
Esophageal Cancer
Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer
Cancer of the esophagus is a very serious cancer. Studies have shown that using chemotherapy and radiation before surgery is the most promising treatment approach, with one quarter to one half of tumors shrinking by 50% or more…
- Trial name
- NCT00160875
- Testing
- Irinotecan hydrochloride trihydrate, Cisplatin
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Lung Cancer
A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.
- Trial name
- NCT00144053
- Testing
- Cisplatin+Vindesine+MMC/ concurrent radiation, Irinotecan+Carboplatin/concurrent radiation, Paclitaxel+Carboplatin/concurrent radiation
- Volunteers
- 450 people
- Sponsor
- West Japan Thoracic Oncology Group
Colorectal Cancer
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00020930
- Testing
- cetuximab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer Metastatic, Fecal Microbiota Transplantation
Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer
This research protocol outlines an exploratory study on the combination of early-life fecal microbiota transplantation (yFMT) with immunotherapy and chemotherapy in patients with microsatellite stable metastatic colorectal cancer…
- Trial name
- NCT07486492
- Testing
- yFMT
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Pancreatic Cancer Resectable
Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer
Pancreatic cancer is one of the most treatment resistant malignancies, often diagnosed at a late stage and associated with poor survival. The 5-year overall survival rate remains around 10%.
- Trial name
- LEFT-PANC (NCT07155629)
- Testing
- mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine
- Where
- 2 sites in Finland
- Volunteers
- 381 people
- Sponsor
- Helsinki University Central Hospital
Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma
- Trial name
- NCT02595931
- Testing
- Berzosertib, Biopsy Specimen, Biospecimen Collection
- Where
- 23 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Esophageal Neoplasms
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after receiving treatment with the drugs irinotecan (also known as CPT-11) and…
- Trial name
- NCT00183872
- Testing
- irinotecan, docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Pancreatic Adenocarcinoma
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT02749136
- Testing
- Preoperative modified FOLFIRINOX and postoperative gemcitabine
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Esophageal Squamous Cell Carcinoma
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).
- Trial name
- NCT03387904
- Testing
- Anlotinib Plus Irinotecan, Irinotecan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Pancreatic Cancer, Unresectable Pancreatic Cancer
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
This is a multicenter, non-randomized, open-label, phase Ib/II study to evaluate the safety, tolerability and efficacy of sotorasib in combination with chemotherapy for patients with advanced KRAS p.G12C mutant pancreatic cancer…
- Conditions
- Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
- Trial name
- NCT05251038
- Testing
- Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU)
- Where
- United States
- Sponsor
- Devalingam Mahalingam
Refractory Solid Tumors in Children
Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Therapeutic solutions to treat solid tumors that are resistant to conventional treatments are now limited. Laboratory data in animals (on pediatric tumors such as brain tumors, sarcomas and neuroblastomas) have shown that the…
- Trial name
- RAPIRI (NCT01282697)
- Testing
- Combined administration of irinotecan and rapamycin
- Where
- 9 sites in France
- Volunteers
- 42 people
- Sponsor
- University Hospital, Strasbourg, France
Advanced Solid Tumor
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing…
- Trial name
- NCT05320874
- Testing
- KM257 Bispecific antibody
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Locally Advanced Rectal Cancer
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
The Efficacy and Safety of Long-Course Preoperative Chemoradiotherapy Combined with Consolidation or Induction NALIRIFOX Chemotherapy in the Treatment of Locally Advanced Rectal Cancer: A Prospective, Multicenter, Phase II Study.
- Trial name
- NCT06894797
- Testing
- Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
This phase II study will evaluate the efficacy of the combination of two monoclonal antibodies (Avastin + Erbitux) with irinotecan, in patients with colorectal cancer progressed after 1st line treatment with FOLFIRI Avastin or…
- Trial name
- NCT00681876
- Testing
- Irinotecan, Avastin, Erbitux
- Where
- 8 sites in Greece
- Volunteers
- 16 people
- Sponsor
- Hellenic Oncology Research Group